Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s ...

The FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active Crohn disease.

Merck has shared data from the pivotal Phase 3 trial evaluating the subcutaneous administration of pembrolizumab together ...

Compared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda was able to reduce the time patients spent in the chemotherapy chair.